Joseph Hsu

• Member of Taiwan Leadership Team: Responsible for covering the Immunology and Neuroscience business unit (2022-2023).
• Key Responsibilities:

- Driving business strategy and ensuring P&L performance.

- Building a high-performing team and fostering a positive culture within the business unit.

- Managing new product launches, including milestone governance, business case development, regulatory and access strategy, and determining the best go-to-market model.

- Providing support and oversight for affiliate risk assessment and action plan development.

• Achieving robust business growth with key products and built firm leading position in IL17/23 classes. This success has been recognized as a best practice globally.
• Immunology Lead in the Northern Asia Pacific Hub (covering Taiwan, Australia, Korea, and Hong Kong) with the objective of fostering collaboration and synergy. This includes leading immunology collaboration forums, business planning, and new product launch readiness.

• Responsible for commercialization for all indications in Bio-Medicines Business Unit, which include Rheumatology, Dermatology and Migraine business. This encompasses to supervise 3 brand managers and 2 district sales managers with 15 sales representatives. Drove organizational change by outsourcing legacy products and prioritizing key brands.
• Led a cross-functional team to adapt Next Generation Customer Engagement (NGCE) strategies, exceeding touchpoint targets during the COVID-19 pandemic.
• Boosted the sales team’s confidence, as evidenced by outperforming the global benchmark in the sales confidence survey, achieved through implementing capability roadmap through innovative way.
• Turned around the Migraine business to hit targets by identifying root causes and leading the team to build the Emgality PSP. This program helps patients navigate the reimbursement process, receive proper education on the disease and product, and use a headache diary to ensure a remarkable patient experience
• The BioMed BU continue strong growth momentum in 2021 with triple digital growth to key brands (Taltz, Olumiant Emgality). Additionally, Taltz DoT SoM achieved marketer leader position in 2021.

• Managed the launch execution in Rheumatology and Dermatology (Olumiant RA, Taltz PsO and PsA), prepared for the upcoming self-pay launch of Olumiant AD, and optimized legacy CNS products (Zyprexa, Cymbalta, and Strattera), contributing US$30M annually.
• Collaborated with the KAM and sales team to accelerate hospital access. Drove HCP adoption through strong multichannel engagement, advancing progress along the adoption ladder.
• Outperformed major competitors in new patient uptake in launch comparisons.
• Served as the North Asia-Pacific Hub Marketing ambassador for brand plan roll-out and launch preparation optimization.

• Responsible for the overall management and performance of the Osteoporosis and Autoimmune portfolio. This included supervising three brand managers (one from the Japan STA project) to develop and implement brand strategies, prepare for the launch of two autoimmune products, and create long-range planning and forecasting models for revenue, budget, and FTE of the brand.
• Led a cross-functional team to create a high-quality reimbursement dossier and engage thought leaders early, accelerating reimbursement timelines for Olumiant and Taltz by 6 and 4 months, respectively.
• Coordinated the environmental shaping campaign to highlight the ongoing burden on RA and increasing awareness of the need for a holistic approach to the management of RA including the importance of Patient Report Outcomes (PROs)

• Managed osteoporosis products, Forteo and Evista, contributing US$ 27 million annually, with 40% of revenue from the self-pay market. Led the team to achieve double-digit volume growth for three consecutive years.
• Created and oversighted patient support programs, including a call center/nurse educator (enrolling over 4,000 patients annually), and self-pay alternative pricing program, significantly increasing new patient uptake.
• Collaborated with Roche Diagnostics to integrate the bone formation marker, P1NP, into clinical practice. This earlier indicator significantly increasing patient adherence by 1.5 times and strategically differentiated Forteo from future competitor.
• Partnered with a medical society to implement the Fracture Liaison Service (FLS) in Taiwan, building an ecosystem to increase the capture rate of fracture patients and improve patient care. Expanded FLS from an initial 6 pilot HPs to over 30 HPs.
• Expanded opportunities in GP channel through business development with Zuellig Pharma.

• Listed and promoted the Diabetes portfolio, including Humalog, Byetta, and Trajenta, in northern Taiwan, increasing revenue by over 300% in three years.
• Achieved top sales performance, ranking annual level 1, in 2010 and 2011
• As Marketing STA in 2012, rolled out the Humalog strategy (targeting patient types and brand messages) to the sales team through the Customer Dialogue Model (CDM), improving the brand’s NSP from weakness to parity